NCT00497081View on ClinicalTrials.gov

Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Substance AbuseHIV Infections
Interventions
DRUG

mirtazapine

mirtazapine 30 mg daily for 3 months

DRUG

placebo

placebo 30 mg daily for 3 months

Trial Locations (1)

94102

San Francisco Department of Public Health, Substance Use Research Unit, San Francisco

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Public Health Foundation Enterprises, Inc.

OTHER

lead

San Francisco Department of Public Health

OTHER_GOV

NCT00497081 - Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors | Biotech Hunter | Biotech Hunter